Clinical utility of ammonia concentration as a diagnostic test in monitoring of the treatment with L-asparaginase in children with acute lymphoblastic leukemia by Czogała, Małgorzata et al.
Research Article
Clinical Utility of Ammonia Concentration as a Diagnostic
Test in Monitoring of the Treatment with L-Asparaginase in
Children with Acute Lymphoblastic Leukemia
MaBgorzata CzogaBa,1 Walentyna Balwierz,1,2 Krystyna Sztefko,3 and Iwona Rogatko3
1 Department of Pediatric Oncology and Hematology, Children’s University Hospital, ul. Wielicka 265, 30-663 Krakow, Poland
2Department of Pediatric Oncology and Hematology, Polish American Institute of Pediatrics, Jagiellonian University Medical College,
ul. Wielicka 265, 30-663 Krakow, Poland
3Department of Clinical Biochemistry, Polish American Institute of Pediatrics, Jagiellonian University Medical College,
ul. Wielicka 265, 30-663 Krakow, Poland
Correspondence should be addressed to Małgorzata Czogała; czogala@tlen.pl
Received 25 April 2014; Revised 7 July 2014; Accepted 11 July 2014; Published 23 July 2014
Academic Editor: Juan Manuel Mej´ıa-Arangure´
Copyright © 2014 Małgorzata Czogała et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
L-asparaginase (ASP) is an enzyme used as one of the basic regimens in the acute lymphoblastic leukemia (ALL) therapy. Because
of the possibility of the enzyme inactivation by antibodies, monitoring of ASP activity is essential. The aim of the study was to
examine if plasma concentration of ammonia, a direct product of the reaction catalyzed byASP, can be used in the assessment ofASP
activity. A group of 87 patients with acute lymphoblastic leukemia treated in theDepartment of PediatricOncology andHematology
in Krakow was enrolled to the study. ASP activity and ammonia concentration were measured after ASP administrations during
induction. A positive correlation was found between the ammonia concentration and ASP activity (𝑅 = 0.44; 𝑃 < 0.0001) and
between the medium values of ammonia concentration and ASP activity (𝑅 = 0.56; 𝑃 < 0.0001). The analysis of ROC curves
revealed the moderate accuracy of the ammonia concentration values in the ASP activity assessment. It was also found that the
medium value of ammonia concentrations can be useful in identification of the patients with low (<100 IU/L) and undetectable
(<30 IU/L) ASP activity.The plasma ammonia concentrationmay reflect ASP activity and can be useful when a direct measurement
of the activity is unavailable.
1. Introduction
L-asparaginase (ASP), an enzyme catalyzing hydrolysis of
asparagine to aspartic acid and ammonia, is one of the
basic regimens used in the treatment of acute lymphoblastic
leukemia (ALL). Neoplastic blasts have reduced expression
of asparagine synthetase and thus need asparagine from the
circulating blood [1]. ASP causes asparagine depletion from
plasma, leading to inhibition of protein biosynthesis in blast
cells, cell cycle arrest, and finally cellular death [2]. The
treatment efficacy is related to the duration and grade of
the reduction of the asparagine concentration in plasma and
cerebrospinal fluid, which depends on the ASP activity. It is
considered that the therapeutic ASP activity is above 100 IU/L
[3–6] but a complete asparagine depletion was observed in
some patients with lower enzyme activity [3, 5, 6].
ASP can be derived from Escherichia coli (E. coli) or
Erwinia chryzantemi (Erwinia) [7]. There are native and
pegylated (PEG-ASP) preparations available, which differ in
pharmacokinetics. Distinct treatment schedules are used for
each preparation to assure the optimal efficacy in most of the
patients.
ASP, as a nonhuman protein, can cause antibodies devel-
opment. Hypersensitivity can be clinically visible or “silent,”
when the drug activity decreases without clinical symptoms
[8–12]. The reported frequency of antiasparaginase antibod-
ies is variable and reaches up to 70% [7, 12]. The frequency
of hypersensitivity reactions ranges from 0% to 45% [7, 12].
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Table 1: The protocols of the ALL IC 2002 program with L-ASPA
administration.
Protocol I 5000 IU/m
2/day—days: 12, 15, 18, 21, 24, 27, 30,
and 33
Protocol II 10000 IU/m2/day—days: 8, 11, 15, and 18
Protocol III 10000 IU/m2/day—days: 1, 4, 8, and 11
HR blocks 1–3 25000 IU/m2/day—days: 6 and 11
Both situations are an indication for switching to anotherASP
preparation (pegylated or from another bacterial source) to
assure the efficacy of the treatment.Therapy monitoring with
a systematic ASP activity measurement seems to be crucial to
recognize silent inactivation and react to it properly.
Ammonia is a direct product of the reaction catalyzed
by ASP. There are few studies concerning the ammonia
concentration during a treatment with ASP [13–17]. A sig-
nificant increase of ammonia levels after an intravenous ASP
administration was described [13, 14, 16]. In some patients,
symptomatic hyperammonemia occurs, especially after PEG-
ASP, probably due to its prolonged half-life [13].
The ammonia measurement, as an easily available, fast,
and cheap test, may be useful as a surrogate parameter of
ASP activity. The aim of the study was to assess the clinical
relevance of ammonia concentration during the ASP therapy.
2. Patients and Methods
Between June 2005 andOctober 2008, 97 childrenwith newly
diagnosed ALL started treatment with the international pro-
gram ALLIC 2002 in the Department of Pediatric Oncology
and Hematology of the Children’s University Hospital in
Krakow, Poland. Eighty-seven patients had blood samples
available for the ASP activity and ammonia concentration
monitoring.
There were 45 boys (52%) and 42 girls (48%), aged from
1.2 to 17 (median: 6, mean: 7; standard deviation/SD/: 4.3
years). 71 patients (81.6%) were diagnosed with common
B-ALL (cALL), 3 (3.4%) with pro-B ALL, 2 (2.3%) with
transitional ALL, and 11 (12.7%) with T-ALL. Among 71
patients with cALL, 25 were in the standard risk group (SRG),
31 in the intermediate risk group (IRG), and 15 in the high
risk group (HRG). One child with proB-ALL and 2 with
transitional ALL were in SRG, 2 patients with proB-ALL and
7 with T-ALL in IRG, and 4 with T-ALL in HRG.
All patients received native E. coli ASP (Asparaginase
Medac, Medac Gesellschaft fu¨r klinische Spezialpra¨parate
mbH, Hamburg, Germany) during induction (Protocol I),
reinduction (Protocol II and III), and HR blocks (Table 1).
The blood samples for ASP activity and ammonia con-
centration were collected before each ASP administration
during induction (3 days after the preceding administra-
tion). Serum for ASP activity evaluation was frozen at
−80∘C until the analysis was carried out. ASP activity was
evaluated with MAAT test (Medac Asparaginase-Aktivita¨ts-
Test, Medac Gesellschaft fu¨r klinische Spezialpra¨parate mbH,
Hamburg, Germany). Blood for ammonia evaluation was
taken before and 24 hours after ASP administrations to hep-
arinized capillary tubes (lithium heparin) and transported on
ice to the laboratory where immediately tested to eliminate
the effect of ASP activity in vitro. In all patients, the activity
of transaminases was monitored to recognize hepatotoxicity.
All analyses were performed in the Department of Clinical
Biochemistry in the Polish-American Institute of Pediatrics
(Jagiellonian University Medical College, Krakow, Poland).
Statistical analyses were performed with the STATIS-
TICA 8 software. Correlations were assessed with Spear-
man correlation analysis. Mann-Whitney U test was used
to compare the differences between the two groups. The
prognostic capacity of ammonia tests was evaluated in terms
of the receiver-operating characteristic (ROC) curve. It was
assumed that a test with an area under curve (AUC) of more
than 0.9 has high accuracy, AUC from 0.7 to 0.9 indicates
moderate accuracy, from 0.5 to 0.7, low accuracy, and below
0.5, a chance result [18].
3. Results
The activity of ASP was analyzed in 374 samples. The
mean ASP activity was 257 (standard deviation (SD): 168)
and median was 248 (range: 0–2063) IU/L. Activity below
100 IU/L was noted in 59 (16%) samples in 19 (21%) patients.
In 15 (4%) samples, activity was undetectable (<30 IU/L). It
was noted in 7 (8%) children.
The ammonia concentration was assessed in 535 samples
taken before the administration of ASP (3 days after the pre-
ceding dose) and in 536 samples taken 24 hours after ASP.The
mean ammonia concentration before ASP administration
was 38 𝜇mol/L (SD: 28 𝜇mol/L) and median was 32 𝜇mol/L
(range: 1.4–208𝜇mol/L). One day after ASP administra-
tion, the mean ammonia concentration was 103 𝜇mol/L
(SD: 64 𝜇mol/L) and median was 88𝜇mol/L (range: 5–
491 𝜇mol/L). The median increase of the ammonia concen-
tration 24 hours after ASP administration with reference to
the concentration before that ASP dose was 51 𝜇mol/L. We
did not observe symptoms of hyperammonemia.
There was a positive correlation between the ammonia
concentration 24 hours and 3 days after ASP administration
and the activity of the drug 3 days after the administration (𝑅
Spearman: 0.34 and 0.44, resp.; 𝑃 < 0.0001).
For each patient, the mean value of ammonia concentra-
tions (separately for the measurements performed 24 hours
and 3 days after the drug administration) and the mean value
of ASP activities were calculated. A significant correlation
between the mean values of the ammonia concentration and
the mean value of ASP activity was found (𝑅 Spearman 0.41;
𝑃 < 0.0001 and 0.56 𝑃 < 0.0001 for ammonia measurements
performed 24 hours and 3 days after ASP administration,
resp.). The mean ammonia concentration was lower in
patients with decreased ASP activity (<100 IU/L) in at least
one measurement than in children with the therapeutic
activity of the enzyme in all tested samples (ammonia 24
hours after ASP: median 70 𝜇mol/L and 106 𝜇mol/L, resp.;
ammonia 3 days afterASP:median 29𝜇mol/L and 42𝜇mol/L,
resp.; 𝑃 < 0.00001).
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Figure 1: The usefulness of the ammonia concentration measured
24 hours and 3 days after ASP administration in detection of low
(<100 IU/L) ASP activity—ROC curve.
On the basis of a ROC curves analysis, the usefulness of
ammonia concentration in detection of low and undetectable
ASP activity was stated (AUC for ammonia concentration
24 hours and 3 days after ASP administration: 0.75 and
0.76, resp.; for low ASP activity; 0.87 and 0.76, resp.; for
undetectable ASP activity—Figures 1 and 2).
The optimal cut-off point for detection of low ASP
activity was 64 𝜇mol/L and 29𝜇mol/L for the ammonia
concentration 24 hours and 3 days after ASP administration,
respectively. For undetectable ASP activity, the ammonia
cutoff was 38 𝜇mol/L (24 hours after ASP) and 24 𝜇mol/L
(3 days after ASP). The parameters assessing the value of
the tests recognizing low and undetectable ASP activity for
different cut-off points of ammonia concentration are shown
in Tables 2 and 3.
Themean value of ammonia concentration during induc-
tion was found to be useful to distinguish between the
patients with the therapeutic ASP activity in all measure-
ments during induction and the patients with low or unde-
tectable ASP activity in at least one determination during
induction (AUC for low and undetectable ASP activity: 0.85
and 0.84, resp.) (Figures 3 and 4).
To identify the patients with low and undetectable ASP
activity, the optimal cutoff points for the mean ammonia
concentration determined 24 hours after ASP administration
were 91 𝜇mol/L and 90.5𝜇mol/L, respectively, and for the
mean ammonia concentration determined 3 days after ASP
administration, 36𝜇mol/L and 29𝜇mol/L, respectively. The
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Figure 2: The usefulness of the ammonia concentration measured
24 hours and 3 days after ASP administration in detection of
undetectable (<30 IU/L) ASP activity—ROC curve.
Table 2: The parameters assessing the ability of the ammonia
concentration to recognize low (<100 IU/L) ASP activity (95% CI in
brackets).
The ammonia concentration after ASP
administration
24 hours ≤ 64𝜇mol/L 3 days ≤ 29𝜇mol/L
Sensitivity 0.64 (0.51–0.76) 0.76 (0.62–0.87)
Specificity 0.75 (0.72–0.76) 0.65 (0.59–0.71)
Positive predictive
value 0.30 (0.24–0.35) 0.27 (0.22–0.30)
Negative predictive
value 0.93 (0.90–0.95) 0.94 (0.91–0.96)
patients with low and undetectable ASP activity for different
cut-off points of themean ammonia concentration are shown
in Tables 4 and 5.
Hepatotoxicity grade III and IV WHO was found in 5
patients.The ammonia concentration in this group of patients
did not differ significantly from the ammonia concentration
in the patients without severe hepatotoxicity. No correla-
tion between the ammonia concentration and transaminases
activity was found.
4. Discussion
ASP is among the most important agents in the therapy
of ALL. Treatment schedules for each preparation assure
clinical efficacy in the majority of patients. Taking into
4 BioMed Research International
Table 3: The parameters assessing the ability of ammonia concen-
tration to recognize undetectable (<30 IU/L) ASP activity (95% CI
in brackets).
The ammonia concentration after ASP
administration
24 hours ≤ 38 𝜇mol/L 3 days ≤ 24 𝜇mol/L
Sensitivity 0.80 (0.50–0.94) 0.75 (0.47–0.91)
Specificity 0.90 (0.89-0.90) 0.74 (0.73–0.75)
Positive predictive
value 0.21 (0.13–0.25) 0.09 (0.06–0.12)
Negative predictive
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Figure 3: The usefulness of the mean value of the ammonia con-
centration measured 24 hours and 3 days after ASP administration
in identifying the patients with low (<100 IU/L) ASP activity in at
least one examination—ROC curve.
account the risk of ASP inactivation by antibodies, the
therapy monitoring with ASP activity measurements is very
important [5, 6, 8].
Ammonia is a direct product of the reaction catalyzed by
ASP and its plasma concentration can be easily measured as
a routine, inexpensive laboratory test. Hyperammonemia is a
well-known complication of ASP administration [13–15, 19].
Steiner et al. described ammonia fluctuations in 10 patients
treated with ASP, up to sevenfold above the normal values
1 day after ASP administration and slow returning to the
normal level within 2 consecutive days, but the authors did
not monitor ASP activity [16]. Watanabe et al. found that ex
vivo ammonia production well correlated with ASP activity,
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Figure 4: The usefulness of the mean value of the ammonia con-
centration measured 24 hours and 3 days after ASP administration
in identifying the patients with undetectable (<30 IU/L)ASP activity
in at least one examination—ROC curve.
were tested [17]. To the authors’ knowledge, till now, there has
been no publication describing a correlation between plasma
ammonia level and ASP activity in larger cohort.
Ammonia produced by ASP reaction is removed in the
liver by incorporation into the urea cycle, so the ammonia
level may be influenced by a hepatic dysfunction. Therefore,
wemonitored the liver function in the studied patients.There
were 5 patients with WHO grade III and IV hepatotoxicity,
but their ammonia concentrations were not significantly
higher than those of other patients.We did not find any corre-
lation between the ammonia concentration and transaminase
activity in our patients.
We analyzed the ammonia concentration 24 hours and
3 days after ASP administration during induction. The
ammonia concentration correlated with ASP activity. The
utility of ammonia measurements in recognizing low and
undetectable ASP activity was assessed. On the basis of an
ROC curves analysis, we found the moderate accuracy of
the test. The optimal ammonia concentration thresholds to
identify low and undetectable ASP activity were determined.
The sensitivity and specificity of these tests were acceptable
especially for undetectable activity of the enzyme, but the
positive predictive values (PPV) were very low, which means
a high percentage of false positive results.
A better test accuracy was found for the mean value
of ammonia concentrations. An analysis of the ROC curve
revealed that the mean value of ammonia concentrations
can be useful to identify patients with low and undetectable
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Table 4: The parameters assessing the ability of the mean value of the ammonia concentrations to recognize patients with low ASP activity
in at least one examination (2 cut-off points, 95% CI in brackets).
The mean value of the ammonia concentration
24 hours after ASP administration 3 days after ASP administration
≤46 𝜇mol/L ≤91 𝜇mol/L ≤20𝜇mol/L ≤36𝜇mol/L
Sensitivity 0.17 (0.04–0.41) 0.89 (0.67–0.99) 0.22 (0.06–0.48) 0.89 (0.67–0.99)
Specificity 0.99 (0.92–1.0) 0.70 (0.58–0.81) 0.99 (0.92–1.0) 0.70 (0.58–0.81)
Positive predictive value 0.75 (0.19–0.99) 0.46 (0.28–0.63) 0.80 (0.28–0.99) 0.46 (0.30–0.60)
Negative predictive value 0.82 (0.72–0.89) 0.96 (0.86–0.99) 0.83 (0.73–0.90) 0.96 (0.89–0.99)
Table 5: The parameters assessing the ability of the mean value of the ammonia concentrations to recognize patients with undetectable ASP
activity in at least one examination (2 cut-off points, 95% CI in brackets).
The mean value of the ammonia concentration
24 hours after ASP administration 24 hours after ASP administration
≤53 𝜇mol/L ≤90.5 𝜇mol/L ≤14𝜇mol/L ≤29 𝜇mol/L
Sensitivity 0.43 (0.10–0.82) 1.0 (0.59–1.0) 0.14 (0.01–0.58) 0.71 (0.29–0.96)
Specificity 0.96 (0.89–0.99) 0.66 (0.55–0.76) 0.99 (0.93–1.0) 0.86 (0.77–0.93)
Positive predictive value 0.50 (0.12–0.88) 0.21 (0.08–0.38) 0.50 (0.13–0.99) 0.31 (0.11–0.59)
Negative predictive value 0.95 (0.88–0.99) 1.0 (0.93–1.0) 0.93 (0.85–0.97) 0.97 (0.90–1.0)
ASP activity in at least one determination during induction.
Using ammonia measurements, 89% of patients with low
ASP activity and 70% of patients with the therapeutic ASP
activity could be correctly recognized and among the patients
with positive results (the mean ammonia level below the
threshold), 46%would be those with lowASP activity. Taking
into account the fact that low ASP activity occurred in 21%
of the examined patients, false positive results would amount
to 23% of all results. That would result in recognizing silent
inactivation in the patient with the therapeutic enzyme activ-
ity and unwarranted switching to another ASP preparation.
As all ASP preparations have similar efficacy and safety
profile while used at proper doses [5, 8, 11], it would have
mainly financial consequences, because of higher costs of the
pegylated preparations or those derived from Erwinia.
A reduction of false positive results could be achieved
by decreasing the threshold of ammonia level. An increase
of false negative results is synonymous with more patients
with unrecognized silent inactivation, at risk of an ineffective
treatment and a symptomatic allergic reaction.
5. Conclusions
The ammonia concentration correlates with ASP activity.
The lower the ammonia concentration is, the higher the
probability of low ASP activity is. Although the ammonia
concentrationmeasurement is not accurate enough to replace
a direct ASP activity assay, it can be helpful when a direct
assay is not available. Identification of the patients with low
and especially undetectable ASP activity “silent inactivation”
with such an easily availablemeasurement could help inmak-
ing decisions about switching to another ASP preparation to
ensure the efficacy of the treatment.
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